3 mai 2016 - FDA convened a joint meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee to discuss results from assessments of the extended-release and long- acting (ER/LA) Opioid Analgesics Risk Evaluation and Mitigation Strategies (REMS)
Ajouté au bande de temps:
Date:
3 mai 2016
Maintenaint
~ Il y a 9 ans et 5 mois